REDWOOD CITY, Calif., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno or the Company) (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced an oral presentation at the Foundation for Prader-Willi Research (FPWR) 2023 Research Symposium, being held October 5-6, 2023, in Denver, Colorado. The presentation features results from the recently completed randomized withdrawal period of Study C602, a long-term treatment study of DCCR (Diazoxide Choline) Extended-Release tablets for the treatment of Prader-Willi syndrome (PWS).
Presentation details can be found below:
FPWR 2023 Research Symposium
Title: | Rationale for and Results from a Randomized Withdrawal Period Following Long-Term Administration of Diazoxide Choline Extended-Release Tablets to People with Prader-Willi Syndrome |
Presenter: | Jennifer L. Miller, M.D. (University of Florida) |
Format: | Oral Presentation |
Date/Time: | Thursday, October 5, 2023 at 2:00 – 2:20 PM CT |
Location: | Westin, Downtown Denver |
Livestream: | Click Here |
About PWS
The Prader-Willi Syndrome Association USA estimates that PWS occurs in one in every 15,000 live births. The hallmark symptom of this disorder is hyperphagia, a chronic and life-threatening feeling of intense, persistent hunger, food pre-occupation, extreme drive to food seek and consume food that severely diminish the quality of life for patients with PWS and their families. Additional characteristics of PWS include ...